Portfolio Alerts Watch List Cart

Pharmaceutical

Refine Search

Product Compare (0)
N
Nectar Lifesciences Ltd
Score 68/100• Decent
Nectar Lifesciences Ltd shows potential in a growing sector, but faces challenges in consistency and valuation, warranting cautious observation.
Company’s Health27/100
Valuation 100/100 · PB 0.3164
Technical Avoid
1M -15.652% 6M -40.625% 1Y -64.036%
Confidence100%
Reasonable PB valuation
Weak ROEPromoter pledge present
#76
View details ➜
M
Makers Laboratories Ltd
Score 68/100• Decent
Makers Laboratories Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
Company’s Health64/100
Valuation 100/100 · PB 0.6789
Technical Avoid
1M -17.202% 6M -6.523% 1Y -11.868%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#77
View details ➜
L
Laurus Labs Ltd
Score 68/100• Decent
Laurus Labs Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics.
Company’s Health68/100
Valuation 20/100 · PB 10.2663
Technical Avoid
1M -2.118% 6M 40.014% 1Y 81.598%
Confidence100%
Weak ROEPromoter pledge present
#78
View details ➜
J
Jubilant Pharmova Ltd
Score 68/100• Decent
Jubilant Pharmova Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
Company’s Health68/100
Valuation 60/100 · PB 2.7324
Technical Avoid
1M -4.211% 6M 16.991% 1Y -11.931%
Confidence100%
Low leverage (D/E)No promoter pledge
#79
View details ➜
J
Jagsonpal Pharmaceuticals Ltd
Score 68/100• Decent
Jagsonpal Pharmaceuticals Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised for investors.
Company’s Health94/100
Valuation 20/100 · PB 6.1975
Technical Avoid
1M -12.389% 6M 1.586% 1Y 22.672%
Confidence100%
Low leverage (D/E)No promoter pledge
#80
View details ➜
J
J B Chemicals and Pharmaceuticals Ltd
Score 68/100• Decent
J B Chemicals and Pharmaceuticals Ltd shows decent potential with a stable growth outlook, but investors should be cautious of execution risks and valuation metrics.
Company’s Health95/100
Valuation 20/100 · PB 7.6056
Technical Avoid
1M -2.377% 6M 4.775% 1Y -11.567%
Confidence100%
Low leverage (D/E)No promoter pledge
#81
View details ➜
I
IPCA Laboratories Ltd
Score 68/100• Decent
IPCA Laboratories Ltd shows potential for growth, but investors should be cautious due to profitability inconsistencies and valuation concerns.
Company’s Health80/100
Valuation 40/100 · PB 3.9237
Technical Avoid
1M -0.978% 6M -5.168% 1Y -23.834%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#82
View details ➜
I
Indoco Remedies Ltd
Score 68/100• Decent
Indoco Remedies Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health56/100
Valuation 60/100 · PB 2.5887
Technical Avoid
1M -1.09% 6M 22.521% 1Y -14.879%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#83
View details ➜
H
Hindustan Bio Sciences Ltd
Score 68/100• Decent
Hindustan Bio Sciences Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised for investors.
Company’s Health33/100
Valuation 20/100 · PB 9.6699
Technical Avoid
1M 0.386% 6M -4.176% 1Y -11.655%
Confidence100%
No promoter pledgeHealthy profit margins
Weak ROEHigh debt/equity
#84
View details ➜
G
Gufic Biosciences Ltd
Score 68/100• Decent
Gufic Biosciences Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
Company’s Health90/100
Valuation 20/100 · PB 6.0646
Technical Avoid
1M -1.07% 6M 6.77% 1Y -10.841%
Confidence100%
No promoter pledge
#85
View details ➜
F
Fortis Healthcare Ltd
Score 68/100• Decent
Fortis Healthcare Ltd shows potential in a growing sector but faces challenges in execution and competition. Caution is advised.
Company’s Health67/100
Valuation 20/100 · PB 8.9547
Technical Momentum
1M 11.709% 6M 62.51% 1Y 75.504%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#86
View details ➜
D
Dr Lalchandani Labs Ltd
Score 68/100• Decent
Dr Lalchandani Labs Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics. Caution is advised.
Company’s Health50/100
Valuation 100/100 · PB 0.989
Technical Avoid
1M -7.143% 6M 81.371% 1Y 16.771%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#87
View details ➜
D
DocMode Health Technologies Ltd
Score 68/100• Risky
DocMode Health Technologies Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health44/100
Valuation 40/100 · PB 4.0838
Technical Momentum
1M 153.452% 6M 119.192% 1Y 16.479%
Confidence100%
Weak ROEPromoter pledge present
#88
View details ➜
C
Concord Biotech Ltd
Score 68/100• Decent
Concord Biotech Ltd shows potential for growth but faces challenges in valuation and execution risks.
Company’s Health94/100
Valuation 20/100 · PB 8.7001
Technical Avoid
1M -7.8% 6M -13.017% 1Y -22.077%
Confidence100%
Low leverage (D/E)No promoter pledge
#89
View details ➜
B
Bharat Parenterals Ltd
Score 68/100• Decent
Bharat Parenterals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health64/100
Valuation 60/100 · PB 2.5077
Technical Avoid
1M -10.192% 6M 25.477% 1Y -16.288%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#90
View details ➜
Showing 76 to 90 of 260 (18 Pages)